Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Orchard Therapeutics Plc ADR
(NQ:
ORTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Orchard Therapeutics Plc ADR
< Previous
1
2
3
4
5
Next >
Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
October 05, 2023
Gainers
Via
Benzinga
Why Is Meiwu Technology (WNW) Stock Up 70% Today?
October 05, 2023
Meiwu Technology is on the move Thursday with heavy trading of WNW stock despite lack of news or filings to explain the rally!
Via
InvestorPlace
Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today?
October 05, 2023
Orchard Therapeutics stock is rising higher on Thursday as Kyowa Kirin agrees to acquire ORTX shares for $16 each in a $387.4 million deal.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
October 05, 2023
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning!
Via
InvestorPlace
Earnings Scheduled For August 3, 2023
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Why Gene Therapy Company Orchard Therapeutics Stock Is Skyrocketing Today?
October 05, 2023
Gene therapy company Orchard Therapeutics Plc (NASDAQ: ORTX) shares are trading higher after it agreed to be acquired by Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, for...
Via
Benzinga
Kyowa Kirin to Acquire Orchard Therapeutics
October 05, 2023
From
Orchard Therapeutics (Europe) Limited; Kyowa Kirin Co., Ltd.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
September 18, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
August 31, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
August 03, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
August 02, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
July 25, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
June 26, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
May 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Why Orchard Therapeutics Stock Is Trading Higher Today
May 19, 2023
Orchard Therapeutics Inc (NASDAQ: ORTX) announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic
Via
Benzinga
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
May 19, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
May 18, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
May 15, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
May 03, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
March 30, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday
March 28, 2023
B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%...
Via
Benzinga
Orchard Therapeutics Completes ADS Ratio Change
March 10, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
March 06, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
March 06, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
March 03, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
February 27, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
February 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Proposed ADS Ratio Change
February 10, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.